Clinical Trial Update: Therapeutic Effect of Recombinant Human Growth Hormone (rhGH) on the Myopathy of Cystinosis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating recombinant human growth hormone for myopathy in cystinosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystinosis
• Myopathy

Drugs mentioned

• Recombinant human growth hormone (somatropin)

Snippet

Sponsor: National Human Genome Research Institute (NHGRI) | Conditions: Cystinosis, Myopathy | Phase 1, Phase 2 | Status: WITHDRAWN